Surein Arulananda

Surein Arulananda

Auto-generated profile, based on publicly available information

Surein Arulananda

Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Erinna LeeErinna Lee
Erinna Lee
THTiffany J. Harris
Tiffany J. Harris
STSharon Tran
Sharon Tran
MEMarco Evangelista
Marco Evangelista
SASurein Arulananda
Surein Arulananda
Walter FairlieWalter Fairlie
Walter Fairlie
Malignant melanoma is one of the most difficult cancers to treat due to its resistance to chemotherapy. Despite recent successes with BRAF inhibitors and immune checkpoint inhibitors, many patients do not respond or become resistant to these drugs. Hence, alternative treatments are still required. Due to the importance of the BCL-2-regulated apoptosis pathway in cancer development and drug resistance, it is of interest to establish which proteins are most important for melanoma cell survival, though the outcomes of previous studies have been conflicting. To conclusively address this question, we tested a panel of established and early passage patient-derived cell lines against several BH3-mimetic drugs designed to target individual or subsets of pro-survival BCL-2 proteins, alone and in combination, in both 2D and 3D cell cultures. None of the drugs demonstrated significant activity as single agents, though combinations targeting MCL-1 plus BCL-XL, and to a lesser extent BCL-2, showed considerable synergistic killing activity that was elicited via both BAX and BAK. Genetic deletion of BFL-1 in cell lines that express it at relatively high levels only had minor impact on BH3-mimetic drug sensitivity, suggesting it is not a critical pro-survival protein in melanoma. Combinations of MCL-1 inhibitors with BRAF inhibitors also caused only minimal additional melanoma cell killing over each drug alone, whilst combinations with the proteasome inhibitor bortezomib was more effective in multiple cell lines. Our data show for the first time that therapies targeting specific combinations of BCL-2 pro-survival proteins, namely MCL-1 plus BCL-XL and MCL-1 plus BCL-2, could have significant benefit for the treatment of melanoma.

1 November 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SASurein Arulananda
Surein Arulananda
HDHongdo Do
Hongdo Do
AMAshan Musafer
Ashan Musafer
PMPaul Mitchell
Paul Mitchell
ADAlexander Dobrovic
Alexander Dobrovic
TJThomas John
Thomas John

1 December 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
EMEmma L. Mitchell
Emma L. Mitchell
Peter Kar Han LauPeter Kar Han Lau
Peter Kar Han Lau
CKChloe Khoo
Chloe Khoo
DLDavid Liew
David Liew
JLJessica Leung
Jessica Leung
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu

1 October 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SASurein Arulananda
Surein Arulananda
BTBibhusal Thapa
Bibhusal Thapa
MWMarzena Walkiewicz
Marzena Walkiewicz
GZGiada V. Zapparoli
Giada V. Zapparoli
DWDavid S. Williams
David S. Williams
TJThomas John
Thomas John

1 March 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JLJason D Lickliter
Jason D Lickliter
HGHui K Gan
Hui K Gan
MVMark Voskoboynik
Mark Voskoboynik
SASurein Arulananda
Surein Arulananda
BGBo Gao
Bo Gao
TMTarek Meniawy
Tarek Meniawy
Purpose: Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian population. Methods: Camrelizumab was administered to patients with advanced solid tumors who had failed standard therapies. In the dose-escalation phase (n=23), camrelizumab was administered intravenously at 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks. In dose expansion (n=26), camrelizumab was given at 200 mg or 600 mg every 4 weeks. Results: Two dose-limiting toxicities were observed during dose escalation: transaminase elevation and diarrhea (both grade 3). Overall, treatment-related adverse events were consistent with the expected toxicity profile of immune checkpoint inhibition, with the striking exception of the dose-related development of angiomatous skin lesions characterized as reactive cutaneous capillary endothelial proliferation. The PK profile showed a dose-progressive increase in half-life from 3 days at 1 mg/kg to 7 days at 10 mg/kg. Moreover, receptor occupancy assays showed a PD-1 occupancy of > 50% in most patients out to 28 days post-dose. The objective response rate was 15.2% (95% CI 6.3– 28.9). Conclusion: Camrelizumab has manageable toxicity and encouraging preliminary antitumor activity in advanced solid tumors in Australia. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02492789.

1 April 2020 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
GLGabrielle Lie
Gabrielle Lie
AWAndrew Weickhardt
Andrew Weickhardt
LKLeighton Kearney
Leighton Kearney
QLQue Lam
Que Lam
TJThomas John
Thomas John
SASurein Arulananda
Surein Arulananda
Malignant pleural mesothelioma (MPM) remains a deadly disease with limited therapeutic options beyond platinum/pemetrexed chemotherapy. Immune checkpoint inhibitors have demonstrated modest benefit in the second to later-line settings. An MPM patient from our institute developed myocarditis and myositis after 2 cycles of second-line nivolumab. Despite immunosuppression with corticosteroids and mycophenolate mofetil, there was ongoing rise in troponin levels which remained elevated for months. The patient developed an impressive but brief response following cessation of nivolumab. Myocarditis and myositis are rare complications of immune checkpoint inhibitors. Clinicians should be aware of these possible complications as myocarditis can result in mortality.